bmiMD

Medications offered

As listed on the provider’s own site. Whether a product is FDA-approved or compounded is the single most important distinction here — we explain why.

• Compounded semaglutide (microdose)Compounded · not FDA-approved

What they publish

bmiMD publishes 1 of 12 standard terms. Fields marked “not publicly disclosed” were not stated on the pages we captured, and we have not filled those gaps with assumptions. Compare disclosure across providers

Membership / programme fee

Published at $99, $109, $119 and $129 per month across tiers, with multi-month totals of $1,188 and $654 also published (as published)

Medication cost

Not publicly disclosed on the pages we captured.

Introductory offer

Not publicly disclosed on the pages we captured.

Insurance

Not publicly disclosed on the pages we captured.

HSA / FSA

Not publicly disclosed on the pages we captured.

Consultation process

Not publicly disclosed on the pages we captured.

Eligibility

Not publicly disclosed on the pages we captured.

Lab work

Not publicly disclosed on the pages we captured.

Pharmacy fulfilment

Not publicly disclosed on the pages we captured.

Shipping

Not publicly disclosed on the pages we captured.

Support services

Not publicly disclosed on the pages we captured.

Cancellation

Not publicly disclosed on the pages we captured.

Refunds

Not publicly disclosed on the pages we captured.

What stands out

• Publishes every dose tier rather than a single 'from' price, so escalation cost is visible.
• Microdosing is not an FDA-approved regimen and the clinical trials studied standard titration, not low-dose protocols.
• Compounded only.

Questions to ask before you pay

These are things we could not settle from published pages, or that we think are easy to misread. Get answers in writing.

• Ask what evidence supports the microdose protocol specifically, and discuss it with a clinician who is not selling it.
• Ask which pharmacy compounds the product and whether it is 503A or 503B.